KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $48.1 million.

  • BeOne Medicines' Capital Expenditures fell 6402.38% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.8 million, marking a year-over-year decrease of 5678.0%. This contributed to the annual value of $492.7 million for FY2024, which is 1232.13% down from last year.
  • BeOne Medicines' Capital Expenditures amounted to $48.1 million in Q3 2025, which was down 6402.38% from $40.2 million recorded in Q2 2025.
  • BeOne Medicines' 5-year Capital Expenditures high stood at $157.9 million for Q3 2023, and its period low was $32.7 million during Q2 2022.
  • Its 5-year average for Capital Expenditures is $94.3 million, with a median of $108.7 million in 2022.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 27163.84% in 2023, then crashed by 6402.38% in 2025.
  • Over the past 5 years, BeOne Medicines' Capital Expenditures (Quarter) stood at $115.0 million in 2021, then grew by 5.55% to $121.4 million in 2022, then rose by 29.34% to $157.0 million in 2023, then crashed by 41.08% to $92.5 million in 2024, then tumbled by 48.01% to $48.1 million in 2025.
  • Its last three reported values are $48.1 million in Q3 2025, $40.2 million for Q2 2025, and $60.0 million during Q1 2025.